AbbVie Tells 7th Circ. Asserting Rights Isn't 'Patent Thicket'
Law360 (December 23, 2020, 7:32 PM EST) -- AbbVie and other pharmaceutical companies are urging the Seventh Circuit to uphold their antitrust win in Humira buyers' suit over the drug's alleged "patent thicket," arguing that the buyers are challenging "run-of-the-mill" patent enforcement conduct the U.S. Supreme Court has already blessed.
The pharmaceutical companies told the court on Monday that the Humira buyers' claim that AbbVie built a "patent thicket" around its blockbuster immunosuppressant drug and cut deals to keep would-be competitors from entering the market is "unprecedented, unsupported, and illogical," and that a lower court was right to dismiss them.
"Accepting [the buyers'] novel theory would fundamentally...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!